BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-97@catalystbrief.girapphe.com
DTSTAMP:20261117T061558Z
LAST-MODIFIED:20261117T061558Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Merck Sharp & Dohme LLC — 9vHPV Vaccine [Jan 2027]
DESCRIPTION:Phase 3 primary completion: Efficacy Against Oral Persistent In
 fection\, Immunogenicity and Safety of the 9-valent Human Papillomavirus V
 accine (9vHPV) in Men Aged 20-45 Years (V503-049).\nSource: https://clinic
 altrials.gov/study/NCT04199689\nhttps://catalystbrief.girapphe.com/e/97?la
 ng=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/97?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
